The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of nivolumab plus or minus ipilimumab in combination with multifraction stereotactic radiosurgery for recurrent high-grade radiation-relapsed meningioma.
 
Jiayi Huang
Research Funding - Cantex Pharmaceuticals; Pfizer/EMD Serono
 
Jian Li Campian
Consulting or Advisory Role - Arbor Pharmaceuticals; Incyte
Research Funding - NeoImmuneTech
 
Feng Gao
No Relationships to Disclose
 
Tanner Michael Johanns
No Relationships to Disclose
 
Annick Desjardins
Stock and Other Ownership Interests - ISTARI Oncology
Consulting or Advisory Role - Celgene; Genentech/Roche
Research Funding - Celldex (Inst); Genentech/Roche (Inst); Lilly (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Symphogen (Inst); Triphase Accelerator Corp (Inst)
Patents, Royalties, Other Intellectual Property - AU 2013347945 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; CA 2,892,183 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; CN 201380070749.7 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; EP 13856989.2 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; HK 15112399.5 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; JP 2015-544130 Div: 2017-084158 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, and a patent; PCT/US17/023148 - Combination Therapy for Cancer Using Oncolytic Poliovirus licensed to Istari and Stock options, ISTARI Oncology; US 15/428510 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent
 
Andrea Wang-Gillam
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Jacobio; Merrimack; Vicus Therapeutics
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CTI (Inst); EMD Serono (Inst); Halozyme (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); pfizer (Inst); Plexxikon (Inst); Precision Therapeutics (Inst); Roche (Inst); Verastem (Inst); Xcovery (Inst)
 
Josh Rubin
No Relationships to Disclose